Merck seeks additional Januvia approvals

Share this article:
Merck has filed applications with the FDA for two additional uses for its diabetes treatment Januvia. Merck is seeking approval for Januvia for the added indications as an adjunct to diet and exercise, in combination with metformin as initial therapy to improve glycemic control; and as an adjunct to diet and exercise, as add-on therapy to a sulfonylurea plus metformin when dual therapy does not provide adequate glycemic control. Januvia is currently approved for use as a monotherapy and as add-on therapy to either metformin or thiazolidinediones, to improve blood sugar control in patients with type 2 diabetes when diabetes when diet and exercise are not enough. Januvia was approved in October 2006. Fourth quarter sales of the drug came in at $42 million.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...